Web Migration React Intern

Withings launches AI heart and lung sound analysis for at-home health monitoring. Health technology company Withings has unveiled a new AI-powered service designed to help families analyse heart and lung sounds recorded at home and provide additional information that can be shared with healthcare professionals. The new StethO Sense service will launch on 1 October 2026 as part of Withings+, the premium membership tier within the Withings app. It works alongside the company's BeamO handheld health device, combining recordings from its digital stethoscope with third-party medical AI technology to analyse heart murmurs and respiratory sounds. Withings says the technology is intended to support - rather than replace - assessment by qualified healthcare professionals, with results designed to provide users with additional health information they can take to their doctor. AI analysis of heart and lung sounds. StethO Sense uses eMurmur Heart AI to analyse heart sounds and technology from StethoMe to assess lung recordings. Users can select a heart or lung recording through the StethO Sense section of the Withings+ app and request an analysis, with results returned within seconds. Heart recordings can be taken at four standard positions on the body, while lung recordings can be made at up to eight positions for adults and six for children. BeamO provides an anatomical diagram to guide users through the recording process. The heart analysis is designed to distinguish between no detected murmur, an innocent murmur and an abnormal murmur, as well as providing heart-rate information and a confidence score. For respiratory recordings, StethoMe's technology can analyse sounds including wheezing, rhonchi and fine and coarse crackles. It can also assess respiratory rate, heart rate and the inspiration-to-expiration ratio. Livia Robic, Product Manager, BeamO at Withings, said: "Every parent knows the moment: a cough at night, and no way to tell whether it matters. With hearts it's even quieter. A murmur can go unnoticed for years. Until now, having those sounds interpreted meant booking an appointment. StethO Sense analyses a BeamO recording in seconds, at home, whenever a family needs it, for children and grandparents alike. It doesn't replace a doctor, but rather, StethO Sense gives you additional health data to bring to one." Potential role in Children's health monitoring. Withings is positioning the technology partly as an additional monitoring tool for parents, particularly during cold and flu season. Respiratory illnesses and wheezing are common among young children. Research published in the New England Journal of Medicine found that around one in three children had experienced a wheezing illness before the age of three. The company says StethO Sense could allow parents to record respiratory sounds when children have coughs or other symptoms and track changes over time. It could also potentially support families managing asthma. Asthma is one of the most common chronic diseases affecting children, and symptoms can be exacerbated by respiratory infections. A six-month observational study published in the Annals of Family Medicine in 2023 examined home monitoring of asthma exacerbations among children and adults using an AI-assisted stethoscope. The researchers reported that the system identified moderate-to-severe attacks with accuracy of more than 92% in children and 81% in adults. StethO Sense can additionally identify and monitor abnormal respiratory sounds associated with conditions including pneumonia and bronchiolitis. However, the company stresses that its AI results are intended to assist diagnosis and should not be regarded as a substitute for clinical assessment. Tracking heart murmurs at home. Another potential application is monitoring heart murmurs. StethO Sense's cardiac analysis is provided by eMurmur, whose Heart AI technology analyses BeamO recordings and identifies whether a murmur appears absent, innocent or abnormal. Across blinded prospective clinical studies, the technology has demonstrated approximately 90% sensitivity and specificity for detecting pathological murmurs, according to Withings. eMurmur Heart AI is CE marked as a Class IIa medical device and can be used across age groups from newborn babies to adults. Heart murmurs are relatively common and are frequently harmless, but some can indicate an underlying heart valve problem. Research published in the European Heart Journal - Cardiovascular Imaging in 2024 involving more than 4,200 older adults found that more than a quarter had previously undiagnosed valvular heart disease. Another service evaluation involving digital auscultation in a community pharmacy found that pharmacists using eMurmur AI referred 70% more patients with non-trivial heart valve disease for echocardiography than GP referrals during the same period. Withings says allowing people to record heart sounds repeatedly could help them monitor changes rather than relying solely on recordings taken during occasional medical appointments. The technology could also have applications within sports health. Heart assessments form part of cardiovascular screening in sports medicine, where clinicians may be looking for signs of conditions including hypertrophic cardiomyopathy. Supporting, rather than replacing, healthcare professionals. The launch reflects the growing use of artificial intelligence and connected devices to move some elements of health monitoring beyond hospitals and GP surgeries. However, Withings has been careful to position StethO Sense as an additional source of information rather than an alternative to professional healthcare. The company's disclaimer states that AI results are "diagnosis-assisting only" and that final clinical assessment must be undertaken by a qualified healthcare provider. StethO Sense will also complement Withings' existing Cardio Check-Up service. Cardio Check-Up allows users to have an ECG reviewed by a cardiologist within 24 hours up to four times a year. StethO Sense instead provides unlimited AI-assisted analysis of heart and lung recordings for Withings+ subscribers. Recordings and results can subsequently be shared with a healthcare professional. Technology also being offered to clinicians. Withings is extending StethO Sense beyond the consumer market through BeamO PrO, the professional version of the device aimed at clinicians and care teams. The company believes the combination of portable hardware and rapid AI analysis could support auscultation assessments across settings including nursing and residential care homes. Previous research into AI-assisted auscultation has suggested the technology could also help healthcare professionals determine which patients require specialist investigation. Withings cites research suggesting AI-supported auscultation could reduce inappropriate cardiology referrals by between 50% and 75%. Clinical assessment and decisions about treatment or referrals would remain the responsibility of healthcare professionals. StethO Sense launching in October. StethO Sense will become available exclusively to Withings+ subscribers from 1 October 2026. Existing BeamO owners who purchased their device before the launch date will be offered a complimentary one-month Withings+ trial. BeamO will be priced at £229.95, with purchases made from 1 October also including a one-month Withings+ trial. Withings+ costs £8.95 per month or £89.50 annually in the UK. BeamO combines a clinical-grade thermometer, oximeter, one-lead electrocardiogram and digital stethoscope within a single handheld device. According to Withings, it enables users to check temperature and record heart and lung sounds in around a minute. StethO Sense is powered by two separately CE-marked Class IIa medical technologies: eMurmur for heart-sound analysis and StethoMe for pulmonary sound analysis. More information about BeamO and StethO Sense is available at withings.com/beam-o. Research and references. Martinez FD, Wright AL, Taussig LM et al. "Asthma and Wheezing in the First Six Years of Life." New England Journal of Medicine, 1995;332(3):133-138. Read the study. Emeryk A, et al. "Home Monitoring of Asthma Exacerbations in Children and Adults With Use of an AI-Aided Stethoscope." Annals of Family Medicine, 2023;21(6):517-525. Read the study. Thompson WR et al. Pediatric Cardiology. 2019;40(3):623-629. DOI: 10.1007/s00246-018-2036-z. The study included 603 patients and reported sensitivity of 93% and specificity of 81%. Martin J et al. International Journal of Pharmacy Practice. 2023;31(Suppl 2)-ii33. DOI: 10.1093/ijpp/riad074.039. Heggdal M, et al. "Heart murmurs in the general population: diagnostic value and prevalence from the Tromsø Study." 2025. Tsampasian V, et al. "Prevalence of asymptomatic valvular heart disease in the elderly population: a community-based echocardiographic study." European Heart Journal - Cardiovascular Imaging. 2024;25(8):1051-1058. DOI: 10.1093/ehjci/jeae127. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. European Heart Journal, 2021;42(1):17-96. Read the guidelines. Further information about the technologies is available from eMurmur and StethoMe. Important: StethO Sense combines BeamO recordings with third-party CE-marked analysis software. AI results are intended to assist diagnosis and do not constitute a final clinical assessment. Users with concerns about their own or their child's health should seek advice from an appropriate healthcare professional.

Withings has launched BodyScan 2, a home health monitoring device priced at $599.95, now available in the United States. The device offers two scanning modes: a 30-second daily scan tracking weight, body composition, heart rate, and vascular age, and a 90-second weekly longevity scan including ECG, blood oxygen levels, and nerve response measurements. BodyScan 2 uses 13-frequency bioimpedance spectroscopy to analyse body composition across six zones, delivering fat and muscle mass readings for individual body segments. The device incorporates ECG, impedance cardiography, and photoplethysmography to monitor cardiovascular health, including atrial fibrillation detection through FDA-cleared software. The system displays real-time measurements on an HD colour screen embedded in its retractable handle. Battery life extends up to 15 months per charge. Purchases include a one-month trial of Withings+ subscription service.

Withings has launched Withings Medical, a clinical care service for Medicare-eligible patients in the US. The service is part of the Centers for Medicare & Medicaid Services' new ACCESS Model, which focuses on outcomes-based chronic disease management. Withings Medical will initially target cardiovascular and metabolic conditions, including hypertension, diabetes, and obesity. Care is delivered through Withings Medical Group, a clinical team that creates individualised treatment plans, prescribes medications, and supports lifestyle changes alongside patients' existing primary care providers. The launch marks a shift for Withings from health monitoring to active care delivery. Founded in 2008, the company previously focused on connected health devices. The new service combines continuous health monitoring with guideline-directed treatment, aiming to address gaps in chronic disease management. The ACCESS Model launched nationally on 5 July 2026.